about
The changing faces of cholangitisBile Acid Metabolism and Signaling in Cholestasis, Inflammation, and CancerWhy Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?The Emerging Role of Soluble Adenylyl Cyclase in Primary Biliary Cholangitis.Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.Functional and structural features of cholangiocytes in health and disease.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunctionA Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary CirrhosisThe inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.Early Molecular Stratification of High-risk Primary Biliary Cholangitis.Environmental Xenoestrogens Super-Activate a Variant Murine ER Beta in Cholangiocytes.The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis.Primary biliary cirrhosis: safety and benefits of established and emerging therapies.It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology.Emerging drugs for the treatment of Primary Biliary Cholangitis.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.Extrahepatic Manifestations of Primary Biliary Cholangitis.Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.Unmet challenges in immune-mediated hepatobiliary diseases.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Genetically engineered two-warhead evasins provide a method to achieve precision targeting of disease-relevant chemokine subsets.Investigational drugs in phase II clinical trials for primary biliary cholangitis.Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.The role of human cytochrome P450 2E1 in liver inflammation and fibrosis.Cholestatic liver diseases: new targets, new therapiesBile acid metabolism and signaling in liver disease and therapyIdentification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis
P2860
Q26747051-3C8E0D2C-F93D-4F8A-9E5C-372F6CA06A78Q26800206-386A620F-93E8-4DE7-BFEE-B26F4681B20BQ33840969-94D64256-C095-4281-84C5-74E7EBE93D72Q33917054-E5653686-F5E2-469B-ABEE-866A5EB44DFAQ34494216-00999935-4118-4C5B-AB7E-88A6D7C585BDQ35933236-CF48DCB5-E9B0-4F67-A4CC-B9CDC0C9AB7FQ36379436-B37089ED-A4F5-4031-BB96-E4368463A4EFQ37208510-096BC802-8AE5-45DE-B0A1-7E4EB5DDF4BDQ37371109-0B74EC5D-3DB1-4D7C-ABAE-EF45639920A1Q37510232-70212BF0-CE47-4A88-86C8-F00F57BB1187Q37708903-ED7C6913-3F78-40D9-81C1-4B6B0526980EQ37714640-A79DE36B-1BB9-4920-9F85-E1CCD21CD7F5Q38554677-8D71E76F-C773-461D-BE28-216182AFC08DQ38620686-CB97EF10-0DA7-4367-BF7F-875BA6DBBCD0Q38744215-CC782CA4-9A4A-477F-91D6-E326213381A8Q39044702-C09AA142-1254-4839-A48E-3441D49A49DBQ39047912-8610F5C4-E3AD-45B5-9CE8-54973DF2859FQ39177903-4577728B-4339-44F8-9696-5110A26683EAQ39723374-F6690F63-5370-43C5-9906-5A37B9E2363CQ40898741-1E360F90-5A7A-4619-A9CE-C71A7CE2C585Q46522249-CEFB1259-0684-418B-84BB-01204AA8C955Q47784988-5B08DFF4-1751-46C5-896B-09C9DECFC920Q48542369-FD55EFFF-F834-4E58-AC42-4F1917198E41Q52624982-9EB48DAC-3F54-4225-B121-C9129556F0ACQ52717837-BB1DBB45-0A2B-42F0-AF0E-8971B3636091Q53098304-B23DA19B-DFFB-4AFA-8623-AB76E621A5FCQ55059313-CC25DAE0-1C3F-430A-B1C6-7D22FAA43C88Q55071942-8D405C0C-1E3F-4306-AC6E-E98F4B9D8B85Q55129692-B40F03A3-2707-4900-BD68-05C1924BE937Q57111104-00EE28A6-94F4-4389-8D6D-FF9902F80CD4Q57128767-C9AACCD9-7956-47F2-A906-DA046F17724DQ58702534-D20610C5-64F4-4DB4-A359-52F69D02E517
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Novel therapeutic targets in primary biliary cirrhosis.
@en
type
label
Novel therapeutic targets in primary biliary cirrhosis.
@en
prefLabel
Novel therapeutic targets in primary biliary cirrhosis.
@en
P2093
P2860
P356
P1476
Novel therapeutic targets in primary biliary cirrhosis.
@en
P2093
David E J Jones
Derek A Mann
Jessica K Dyson
Keith D Lindor
Ulrich Beuers
P2860
P2888
P304
P356
10.1038/NRGASTRO.2015.12
P407
P577
2015-02-03T00:00:00Z